Integra Therapeutics is a biotech company engineering the next generation of gene writing tools to cure genetic diseases At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery.

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe respiratory diseases Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing

169 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. biotechnology, research, T cell, biologics, and science

211 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Modern cancer care for the next billion people Hedera Dx enables health systems, patients and drug development programs to easily adopt advanced molecular testing and real-world evidence (RWE) capabilities. Join us on hederadx.com to learn more! Oncology, Next-Generation Sequencing, Liquid Biopsy, ctDNA, IVDR Compliance, Medical Device, Precision Medicine, and RWE

164 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking access to genes with unparalleled accuracy Our mission is to enable synthetic biologists, by using our technology to unlock access to genes with unparalleled accuracy. We produce genes for a range of biotechnology customers including those in the pharmaceutical, agriculture and diagnostics sectors. Our technology offers access to long and complex gene sequences, which are normally difficult to produce. We are based in Cambridge UK, but we serve companies across the world. Camena's technology is positioned to enable researchers and the synthetic biology revolution. Twitter: @camenabio DNA synthesis, Complex genes, Synthetic Biology, synbio, and Gene synthesis

122 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The multiomics information company, specialist in whole genome sequencing and interpretation. Owner of Dante Labs. Dante Omics AI merges multiomics data with advanced artificial intelligence to drive innovation in precision medicine. The company leverages its proprietary Dante Platform to provide superior results to clinicians, researchers and individuals. The company continues to pioneer cutting-edge technologies that deepen our understanding of human biology and empower transformative healthcare solutions worldwide. genomics, AI, GenAI, omics, multiomics, longevity, DNA Tests, genomics, transcriptomics, proteomics, and spatial

98 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Generative A.I.

less complexity. more biology. At Chromodynamics, we are on a mission to deliver instruments that eliminate guesswork from drug development and prescription. Our unique technology allows for an enormous improvement in speed, efficacy, and cost with which exciting new treatments like immunotherapy are developed. We have been recognised as one of the most promising startups in the Eindhoven Brainport region and are expanding our team to ramp up our product development. Imaging systems, Multispectral imaging, Real-time analysis, Chemical imaging, Spectroscopy, Scientific instruments, Contract research, and Data analysis

931 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Engineering the future of aging medicine. We are advancing small molecule therapeutics for age-related diseases. Our platform enables precise, dynamic control of biological targets and pathways, generating high-fidelity datasets that, combined with advanced AI, unlock systematic exploration of previously inaccessible chemical space. At its core are our ultra-large, in-house aging datasets, which provide a rich foundation for target identification and therapeutic discovery. biotechnology, aging, drug discovery, machine learning, synthetic biology, optogenetics, artificial intelligence, rejuvenation, molecular biology, novel therapeutics, therapeutics, and small molecules

178 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning

Complete genes for complete cures Kano Therapeutics is a biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials: circular single-stranded DNA. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them. Biotechnology, DNA therapeutics, Gene therapy, CRISPR, and Biological engineering

104 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We're committed to translating our ground-breaking science into genomic medicines that transform patients’ lives. For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. Our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. Currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. To learn more about Sangamo, visit the our website at www.sangamo.com. Biotechnology, Genome Editing, Gene Therapy, MPS II, MPS I, Hemophilia A, Hemophilia B, Beta Thalassemia, Gene Therapy, Fabry, …

81 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

An independent news organization covering genetics, genomics, and molecular diagnostics. GenomeWeb is an independent online news organization based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and molecular diagnostics. GenomeWeb’s editorial mission is to cover the scientific and economic ecosystem spurred by the advent of high-throughput genome sequencing. We operate the largest online newsroom focused on advanced molecular research tools in order to provide our readers with exclusive news and in-depth analysis of this rapidly evolving market. GenomeWeb users …

55 similar entities Type: SMB Activities: deeptech biotech

Our mission is to produce non-transgenic, regulatory free, sustainable, consumer oriented genome edited plant products. PLANTeDIT is the first biotech company dedicated to use patented next generation genome editing tools CRISPR/Cas9 RNPs® from our key collaborator Toolgen (http://toolgen.com/?lang=en) with our transformation technology for efficient direct delivery and swift regeneration of genome edited plants. Our mission is also to revolutionize plant transformation technology with our innovative, universal, cost effective, swift transformation system applicable to broad a range of crop species for direct delivery of genome editing tools. Further, PLANTeDIT aims to develop highly pure mammalian protein and human drugs at cost …

57 similar entities Type: Startup Activities: biotech deeptech agritech Technologies: Synthetic Biology

VectorBuilder is a global leader in gene delivery technologies. As a trusted partner for thousands of labs and biotech/pharma companies across the globe, VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside. VectorBuilder is the future of gene delivery. Our mission is to provide end-to-end solutions for all gene delivery needs spanning both research and therapy. We strive to offer innovative and high-quality products and services while maintaining rapid turnaround and exceptional affordability. Our “white-glove” customer care is supported by a PhD-level team with decades of collective experience to …

75 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

Transforming health, healthcare and drug discovery and development through the power of genomics We are a pioneering transatlantic TechBio company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalised estimates of risk for all the common diseases and cancers, …

183 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Seamless Therapeutics is overcoming the boundaries of gene editing by unlocking the full potential of recombinases. Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.

63 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

RNA Therapeutics We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiRTM platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

113 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology Data Analytics

We are a genetics company transforming the way pharmaceutical companies develop drugs to include non-european data. Biomedical research driving transformation in healthcare through genomics. Complete our 3-min survey: https://forms.gle/MFApRSWVno63c1Fx5 Biomedical, Biodiversity, Genome Research, Healthcare, Environment, Conservation, Caribbean, and Biotech

204 similar entities Type: Startup Activities: deeptech biotech Technologies: Data Analytics

Synthetic DNA for Health & Sustainability Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, and industrial chemicals, scientists use our synthetic genes, oligo pools, biopharma services, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise …

95 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

512 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

AI for digital twin of cells DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, …

294 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Deep Learning SaaS

Cyto-genomic technology to measure chromosomal health Cell Environment is a company created in 2016 that developed a new automated cyto-genomic approach combining new cytogenetics techniques with molecular genetics, based on 20 years of academic and private research. It allows to precisely analyse repetitive sequences (50% of the genome) as telomeres & centromeres and detect other chromosomal aberrations. This technology can be applied to better stratify populations for precision medicine in oncology for instance, to help diagnose some conditions as infertility or prenatal conditions, to measure toxic effects of certain treatments (in oncology) or of radiations, to measure the quality of …

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Patient-based drug discovery We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine. AI image and data analysis, biology, high content screening, high throughput screening, deep learning, assay development, patient stratification, pyschiatric disorders, and cardiac muscle

281 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. Synthetic Biology

Optimizing your gene transfer workflows with GEG Tech technologies GEG Tech is a French Deeptech company specializing in genetic engineering, developing innovative technologies for advanced therapies, including gene therapies, vaccines, cancer immunotherapies and dermatology. GEG Tech designs DNA vectors and has invented a new generation of biological mRNA vectors that are far more efficient than chemical nanoparticles and safer than viral vectors. With 12 years of experience in genetic engineering, the company operates as a studio-lab, serving clients primarily in the United States and Europe. GEG Tech’s scientific team originates from the CNRS, and its laboratory is based on the …

78 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

CircaGene platform for personal genetic tests World's first Patented Incognito DNA Encryption with actionable result The mission of CircaGene is to provide world-class BioInformatics Services to protect and improve Public Health both at population and individual levels. Bioinformatics, Sequencing, Genomic, Genetic Data Privacy, Actionable Genomics, Genetic Coach, Optimised Lifestyle, Science in your side, DNApower, and Genetic Heroe

66 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Data Analytics

Reach the full potential of Gene Editing Algenscribe is developing a genome editing platform to improve human health. Algenscribe is developing new patented genome editing tools that find applications in the fields of gene and cell therapy, oncology and bioproduction. Our mission is to reach the full potential of genome editing. Genone editing for human health and Gene Therapy

60 similar entities Type: Startup Activities: healthtech deeptech Technologies: SaaS

Transforming how molecular biology translates to human health, personalized medicine and synthetic biology DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAXTM️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine. Synthetic Biology, Biotechnology, DNA synthesis, Sciences, Research, Development, Start-up, and Technology

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Since more than 10 years, AnyGenes® scientists develop and produce innovative high throughput screening products for signaling pathway analysis. These kits and reagents allow high throughput transcriptomic analysis of a large collection of signaling pathways in many species, biomarkers identification and validation, as well as validation of microarrays results. AnyGenes®, with its innovative & cost effective technologies, products and its proprietary molecular platform, helps scientists to accelerate their projects, publications, and biotech companies for drug development and biomarkers validation. Located in Paris, within Tenon Hospital in the 20th arrondissement, AnyGenes® constitutes a key player in the Biotechnology field. Supported by …

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies. Single molecule analysis, RNA Drug Discovery, Protein-protein Interaction Analysis, Biophysics, Drug Discovery, Compound Screening, biomolecular interactions, and interactomics

307 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Frontier models for all molecules of life. We are making biology programmable to transform health and sustainability for the benefit of all. We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizing existing enzymes, and advancing genetic engineering. Contact us to work with us today.

134 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: A.I. Generative A.I.

Ultimate predictability Since 1999, genOway aims at bridging the gap between preclinical findings and clinical success with advanced, genetically engineered preclinical models and solutions. From customized mice and rats to ready-to-use cell lines, our solutions provide increased predictability and accelerate therapeutic breakthroughs. We work with 17 of the world’s Top pharma companies—as well as leading biotech firms, CROs, and academic institutions. At the heart of genOway is a team of 150+ skilled professionals, from 17 nationalities, all committed to advancing preclinical research. What We Offer • A catalogue of validated, ready-to-use mice and cell lines—developed in partnership with biopharma leaders …

148 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking in vivo cell therapy with the next generation of gene editing technology Brink Therapeutics is developing next-generation recombinases — ultra-precise and efficient enzymes that surpass CRISPR-Cas9. We aim to revolutionize Cell and Gene therapies, enabling large-scale production to treat cancer, genetic disorders, and other diseases.

105 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A scalable in-vivo genetic medicine platform At Immitra Bio, we are pioneering a novel genetic medicine platform. Our innovative approach enables precise, durable, and safe gene modifications within blood stem cells, laying the foundation for scalable, curative in-vivo therapies.

122 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We bring life-saving genomics to hospitals, physicians and patients everywhere. Quantgene decentralizes genomics to bring precision medicine to everyone. Our turnkey genomics platform empowers hospitals to move life-saving genomic diagnostics inside their organizations, unlock powerful new sources of revenue and become a driving force in clinical discovery. From complete genomic profiling to hereditary cancer testing and multi-cancer early detection, we help hospitals, physicians and patients to unlock the full power of precision genomics. Cancer diagnostics, biotechnology, genomics, machine learning, oncology, precision medicine, cancer screening, deep sequencing, cancer, innovation, AI, and Cancer Detection

92 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

The Cell Coding Company bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable …

330 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A new hope for patients affected by Alzheimer’s disease CaSRevolution is a research company specialized in devising innovative therapies for neurodegeneration diseases We have discovered a new mechanism that explains the progression of Alzheimer’s Disease and identified a potential therapeutic approach biotech, neurodegeneration, startup, and alzheimer

129 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Consent-first clinico-genomic data that streamlines rare disease research. GeneHub is consent-first, real-world data from which Biopharma and CROs can recruit. GeneHub's mission is to make patient data move at the speed of science — with permission, with privacy, and with patients in total control. GeneHub is London-based and pre-seed backed by VCs and Innovate UK. Its initial focus is on rare diseases, where unmet needs are jaw-dropping.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Safe and durable gene editing solutions for patients Alia Therapeutics is a biotechnology company dedicated to developing next-generation gene editing therapies for Inherited Retinal Diseases, starting with Retinitis Pigmentosa a leading cause of inherited blindness worldwide. IRDs are marked by extreme genetic and clinical heterogeneity, making traditional therapeutic approaches difficult to scale and leaving many patients without viable treatment options. Alia addresses this challenge through a modular, mutation-agnostic approach enabled by its proprietary CRISPR platform. At the core of Alia’s technology are novel, next-generation CRISPR enzymes discovered in-house with superior in vivo editing efficacy and delivered using a single AAV …

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Powering the future of gene editing development. Broken String Bioscience’s technology platform, INDUCE-seq®, supports the development of cell and gene therapies that are safer by design. INDUCE-seq®, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs.

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS

Expediting the discovery and translation of precision medicine. web-based no-code auto machine learning platform that's tuned for analyzing biomedical data to find disease markers, therapies and drug targets machine learning, signature building, biomarker discovery, and precision medicine

173 similar entities Type: SMB Activities: biotech Technologies: A.I. A.I. - Machine Learning

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

296 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Turning the Dark Genome into Novel Medicines. Most of the genome is uncharted. We drew a map. AMPLY Discovery is a UK biotech turning the 98% of the genome largely ignored by drug developers into a pipeline of first-in-class therapeutics. Running six AI engines and two wet labs across one closed loop between silicon and bench. Based in Belfast, Northern Ireland. Spin-out from Queen's University Belfast. Biotechnology, Anti-infectives, Drug Discovery, AI, Machine Learning, Healthcare, Genomics, Metagenomics, Cancer, Biologics, Metabolic Diseases, Natural Drugs, Nutraceuticals, Bioinformatics, lncRNA, siRNA, and Dark Genome

91 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning

Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease

257 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

The Bedrock of Biotech Genetic Engineering & Biotechnology News (GEN) is the flagship publication of Mary Ann Liebert, Inc. Celebrating its 40th anniversary in 2021, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new tools and technologies, investment growth, and career opportunities. Through its cornerstone Magazine, dynamic Website, high-frequency eNewsletters, and innovative suite of multimedia, GEN is the 360-degree resource that researchers and executives depend on for information that is pivotal for their success. GEN’s breadth of editorial coverage is unrivaled, providing …

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Technology to ignite the biology revolution We are a Cambridge-based company developing a radically different approach to gene synthesis. Our desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists'​ ability to use synthetic biology on a scale not currently possible. Biotechnology, Synthetic Biology, DNA synthesis, Gene synthesis, and synbio

132 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

In-House No-Code Genomics Platform helping Geneticists for Enhanced Research Efficiency and Accelerated Innovations We offer time and cost saving in-house, secure no-code genomics data management, analytics and visualization platform for molecular geneticists, bioinformaticians for enhanced research efficiency and accelerated innovations in agrigenomics and life sciences organizations. We offer no-code genomics software solutions for common challenges routinely that geneticists and bioinformaticians face in their NGS workflow specifically in secondary and tertiary analyses. Our platforms have been proven to create values for the life scientists and their organizations by saving time and cost, accelerating time to market and by providing higher data …

109 similar entities Type: Startup Activities: biotech it services Technologies: Data Analytics SaaS

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients …

83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Love your DNA 🧬 Genetic progress in recent years is only comparable to the advancements in the field of computer science. Our vision is to enable everyone to learn about their unique genetic code and inspire new ideas and scientific approaches. Since the completion of the human genetic code in 2003, the number of studies and sources of information on genetic markers, along with the scientific drive to better understand the genotype-phenotype has grown exponentially. In ADNTRO we help you navigate all present & future findings. Invest in your DNA – its for Life. GWAS, Genetics, Education, bioinformatics, Polygenic risk …

88 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. - Machine Learning

A revolution in gene therapy for neurodegenerative disorders. IMPORTANT NOTICE: Fraud warning for candidates. Please click the link below under "Website" or read the following before applying: https://aviadobio.com/careers/. At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize …

159 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing our proprietary AxiomerTM RNA-editing platform technology Changing lives is what drives us at ProQR Therapeutics. We are advancing our proprietary AxiomerTM RNA-editing platform technology. Our highly energetic team strives to combine innovative technologies and entrepreneurism to make a meaningful impact on the lives of individuals and the people around them. If you are up to this challenge and like to be part of our team, check out our website for vacancies: http://www.proqr.com/careers/ RNA therapeutics, Drug development, Rare Diseases, Genetic Diseases, Orphan drugs, Pharmaceuticals, and RNA editing

174 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlock genomic insights Emedgene is on a mission to unlock genomic insights for the world’s health organizations by providing data-driven AI solutions for genomic diagnostics and discovery at scale. We work with leading healthcare and life sciences organizations to enable precision medicine programs, enable high throughput diagnostics and accelerate the pace of research. Genomics, Human Genetics, Big Data, and Algorithms

214 similar entities Type: Startup Activities: biotech deeptech it services Technologies: A.I. A.I. - Machine Learning

Applying AI to drug discovery Evariste is an AI-enabled drug discovery company developing small molecule inhibitors of next generation synthetic lethality targets. Using our automated AI-enabled drug discovery platform, Frobenius, we are able to progress preclinical drug discovery projects at scale and with unparalleled efficiency. Technology , Software, Biotech, Research, and Drug Discovery

209 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Harnessing the Power of Epigenetic Editing Chroma Medicine is pioneering a new class of single-dose genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, revolutionizing the treatment of disease. Epigenetics is nature’s central mechanism for gene regulation, governing cell phenotype and function by precisely controlling gene activity without changing the underlying DNA sequence. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma Medicine is working at the cutting edge of precision genomics, building an entirely new class of therapeutics to achieve unparalleled control of gene expression. *Note: Be aware of fraudulent recruiting advertisements and scams: …

90 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Powering the next wave of genetic medicines through superior delivery ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology

148 similar entities Type: Startup Activities: deeptech biotech nanotech Technologies: Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

589 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Genetics is advancing at a rapid pace, transforming research and revolutionising the way we diagnose and treat complex diseases such as heart disease and cancer. We are a team of scientists and developers specialised in genetics and bioinformatics, determined to increase access to genomic medicine in the clinic. We develop innovative solutions to make genomic medicine more accessible, partnering with a portfolio of private and public laboratories in the UK and overseas. Our approach is strongly shaped by our scientific background and experience. Our flexible, powerful online ordering platform for genetic tests enables clinicians to find and order tests for …

129 similar entities Type: Startup Activities: biotech deeptech Technologies: SaaS

Developing the Next Generation Gene Editing Technology Pencil Biosciences is developing a truly innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. Genome Engineering, Research and Development, and Gene Editing

183 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

An innovative gene editing company discovering and developing curative treatments for genetic diseases Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing …

68 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Foundation models for RNA-centric drug discovery At Atomic AI, we build artificial intelligence to pioneer new frontiers in drug discovery. Our unique R&D platform, an early version of which was featured on the cover of Science, enables the design of novel, RNA‐centric medicines for areas of high unmet need. We continue to advance this platform by developing new machine learning methods and unique foundation models fueled by our large-scale, in-house experimental data collection. We are an interdisciplinary team of scientists and engineers and believe our people are our greatest strength and the key to our success.

174 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology Generative A.I.

Building the future of AI drug development with the data that matters. CAR-T is for more than just oncology. Using the full potential of gene editing, we are creating a therapeutic platform for cell based therapies that are not just disease modifying: they are curative and definitive. Cell-based Therapies and Machine Learning

158 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: Synthetic Biology SaaS A.I. Generative A.I.

Let’s cure from the beginning! Genome editing-based therapies become the predominant technology of the 21st century with promising statements about genetic diseases treatments. Genome editing tools recently emerged but they suffer from an absence of standardization and their applications remain limited. In this context, Quidditas developed a novel genome editing platform which permits an absolute genetic recombination. Compatible with a larger scope of applications, from bioprocess improvement to genetic disorders treatment, this revolutionary technique will have a major impact in the synthetic Bio field. So “Let’s cure from the beginning!” Genome Editing

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We are reimagining the entire drug discovery process from first principles with an AI-first approach. Isomorphic Labs is here to advance human health by building on and beyond the Nobel-winning AlphaFold system. Our interdisciplinary team has developed a unified, state-of-the-art drug design engine that will transform how we design new drugs, and ultimately change the way medicine will help and heal people. Every day, and with each new breakthrough, we’re getting closer to achieving our ambitious mission to one day solve all disease Drug Discovery and Design, machine learning, research, engineering, chemistry, and biology

208 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I.

High-content CRISPR screening in primary human cells for unbiased target discovery and AI-driven foundation models Myllia Biotechnology is redefining functional genomics by uniting CRISPR-based perturbations, single-cell resolution, and advanced computational modeling. Our platform integrates high-content CRISPR screens with single-cell RNA sequencing in primary human cells to deliver deeply physiologic, mechanistic insights. By generating large-scale, custom perturbation datasets, we enable AI-driven foundation models of virtual cells that infer causal relationships, reveal mechanisms of action, and accelerate unbiased target discovery. This end-to-end approach produces genetically validated, high-value targets for early-stage drug development and generates AI-ready data at a scale and fidelity previously …

79 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-shelf, and we are advancing our pipeline of off-the-shelf, or allogeneic, cell therapies from our CAR-T cell therapy platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Next-generation CRISPR genome editing, allogeneic CAR-T cell therapies, oncology, and …

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology